[Clinical phase II study of K-18 in cancer of the digestive organs].
D000230:Adenocarcinoma / Q000628:therapy*; D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D000922:Immunotoxins; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000628:therapy*; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004338:Drug Combinations; D000922:Immunotoxins; C045927:K-18 conjugate; D005719:gamma-Globulins; D008558:Melphalan